In recent years, some policymakers have suggested the United States is too dependent on imports of certain products from countries like China. With the outbreak of COVID-19, the calls to reshore the supply chain of a number of products, including pharmaceuticals and other medical equipment, have intensified.
Policymakers hoping to usher in a new era of industrial policy should be cautious. Reshoring the entire pharmaceutical supply chain would increase costs for consumers, dampen innovation and hurt the competitiveness of a global industry.
In conjunction with the release of a new R Street white paper exploring all of the major issues surrounding the pharmaceutical supply chain, we invite you to a webinar that will dispel a number of myths and offer positive, concrete ideas that are available to policymakers.
Clark Packard (Moderator)
Resident Fellow and Trade Policy Counsel, R Street Institute
Associate Fellow, R Street Institute
Director of Immigration and Trade Policy, American Action Forum